TrialsgrambetaRCTs are beautiful

KEYNOTE-177

2020

Pembrolizumab in MSI-H/dMMR Metastatic Colorectal Cancer

In 307 patients with untreated MSI-H/dMMR metastatic colorectal cancer, pembrolizumab improved progression-free survival compared with chemotherapy ± targeted agents.

Result

Efficacy: Progression-free survivalHR 0.6

Below 1 favours pembrolizumab, above 1 favours chemotherapy ± targeted agents.

Event rates Pembrolizumab 16.5 vs chemotherapy ± targeted agents 8.2 months

Also reported: No OS benefit at primary readout (heavy crossover).

Original publication
Subtopic
MSI-H mCRC
Design
Open-label RCT
Relevance
Important: one of several pillars.
Source
André T, et al. N Engl J Med. 2020;383(23):2207-2218.doi 10.1056/NEJMoa2017699

Discussion & critique

Established checkpoint inhibition as first-line standard in MSI-H/dMMR mCRC. Universal MMR/MSI testing at diagnosis is now non-negotiable.